Description
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Location: CPMC (San Francisco)
Please contact: Clinicalresearch@sutterhealth.org for information about Merck 7339-007
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Kevin Kim, MD, Lejla Delic, MD
Recruitment Status
Active, Recruiting
Start Date
December 20, 2019